XyloCor
Biotechnology · Cell & Gene Therapy
Overview
Gene therapy for advanced coronary artery disease. XyloCor Therapeutics is focused on improving the lives of patients through our commitment to advancing novel therapies for coronary artery disease.
Financials
Total raised
$300k
Latest round
Grant
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Grant | 2023 | $300k | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
XyloCor Appoints John Tucker as President and Chief Executive Officer
KING OF PRUSSIA, Pa., March 05, 2026--XyloCor Therapeutics, Inc. (XyloCor or the Company), a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular disease, today announced the appointment of John Tucker as
Read more
Report
XyloCor Therapeutics: $67.5 Million (Series B) Raised For Advancing Clinical Development Of Gene Therapy In Cardiovascular Disease
XyloCor Therapeutics - a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease - announced the completion of a $67.5 million Series B financing. And the new investment will support a randomized, double-blind P
Read more
Report
XyloCor Therapeutics Presents Phase 2 Data Highlighting Safety and Efficacy of XC001 at the European Society of Cardiology (ESC) Congress 2023
Read more
Report
XyloCor gene therapy hits goals, paving way for phase 3 in cardiovascular space with no current treatment
Read more
Report
Gene therapy developer XyloCor adds $22.6M to expand clinical trial plans
With the extension to its Series A financing, XyloCor plans a clinical trial testing its gene therapy as an adjunct to coronary artery bypass graft surgery. A study in refractory angina is already underway.
Read more
Report
XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease
XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for the significant unmet patient needs i...
Read more
Report
XyloCor Therapeutics Doses Patients in Phase 1/2 Trial Evaluating Novel Gene Therapy XC001 in Refractory Angina
Read more
Report
Xylocor strikes chord in CAD, lands $17M series A for gene therapy bid
Four years out from opening its doors, Xylocor Therapeutics Inc. closed a $17 million series A as it prepared to move lead candidate XC-001, a cardiovascular angiogenic gene therapy, into phase I in individuals with refractory angina who have no other tre
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Chesterbrook
United States
HQ
50-200 est. staff